{"id":40702,"date":"2024-03-27T10:00:13","date_gmt":"2024-03-27T09:00:13","guid":{"rendered":"https:\/\/www.satt.fr\/albupad\/"},"modified":"2024-03-27T10:03:28","modified_gmt":"2024-03-27T09:03:28","slug":"albupad","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/albupad\/","title":{"rendered":"La Success Story du mois : ALBUPAD"},"content":{"rendered":"<div id=\"pl-40702\"  class=\"panel-layout\" ><div id=\"pg-40702-0\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-0-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><span style=\"font-size: 14pt; color: #c90f4c;\">#Un mat\u00e9riau innovant pour r\u00e9volutionner la d\u00e9livrance de m\u00e9dicaments !<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-1\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-1-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-1-0-0\" class=\"so-panel widget widget_media_image panel-first-child panel-last-child\" data-index=\"1\" ><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"93\" src=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/miniature-1-300x93.png\" class=\"image wp-image-40675  attachment-medium size-medium\" alt=\"\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/miniature-1-300x93.png 300w, https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/miniature-1-150x46.png 150w, https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/miniature-1-200x62.png 200w, https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/miniature-1.png 489w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/div><\/div><div id=\"pgc-40702-1-1\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-1-1-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"2\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><strong>La nouvelle startup ALBUPAD vient de voir le jour \u00e0 Strasbourg, propuls\u00e9e par la SATT Conectus avec le soutien d\u00e9terminant du Carnot MICA. Spin-off de deux laboratoires de recherche publique strasbourgeois et incub\u00e9e chez SEMIA, ALBUPAD propose un nouveau mat\u00e9riau innovant \u00e0 base d\u2019albumine, 100% naturel, biocompatible et biod\u00e9gradable.<\/strong><\/p>\n<p>Il offrira aux patients souffrant de maladies chroniques ou de cancers un nouveau syst\u00e8me de d\u00e9livrance progressive et contr\u00f4l\u00e9e de m\u00e9dicaments sur une p\u00e9riode pouvant couvrir plusieurs semaines. Cette technologie de rupture permettra ainsi d\u2019\u00e9viter les prises quotidiennes, les erreurs de dosage, les risques d\u2019oubli et limitera les effets ind\u00e9sirables.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-2\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-2-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-2-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"3\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<h2 style=\"text-align: center;\"><strong>Un dispositif innovant pour la d\u00e9livrance de m\u00e9dicaments<\/strong><\/h2>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-3\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-3-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-3-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"4\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p>ALBUPAD d\u00e9veloppe <strong>un nouveau syst\u00e8me implantable dans le corps<\/strong> <strong>humain<\/strong>, <strong>capable de lib\u00e9rer un m\u00e9dicament de mani\u00e8re progressive, sur une longue p\u00e9riode et de mani\u00e8re localis\u00e9e<\/strong>. Con\u00e7u avec des <strong>composants uniquement naturels,<\/strong> tels que <strong>l\u2019albumine<\/strong>, une prot\u00e9ine naturellement produite par le corps, <strong>cet implant<\/strong> <strong>se d\u00e9grade naturellement<\/strong> apr\u00e8s avoir lib\u00e9r\u00e9 lentement le m\u00e9dicament sur le site d\u2019int\u00e9r\u00eat.<\/p>\n<p>Au-del\u00e0 de son excellente biocompatibilit\u00e9, le nouveau mat\u00e9riau ALBUPAD se pr\u00eate au<strong> chargement de tous types de mol\u00e9cules actives<\/strong> (petites mol\u00e9cules hydrophiles et hydrophobes, peptides ou prot\u00e9ines th\u00e9rapeutiques) et permet une lib\u00e9ration r\u00e9guli\u00e8re et prolong\u00e9e de ces actifs. Il est de plus produit \u00e0 partir d\u2019un <strong>proc\u00e9d\u00e9 de fabrication \u00ab\u00a0vert<\/strong>\u00a0\u00bb, qui exclut les solvants organiques et les agents toxiques.<\/p>\n<p>Les b\u00e9n\u00e9fices sont triples\u00a0:<\/p>\n<ul>\n<li><strong>Des traitements plus efficaces<\/strong>, les mol\u00e9cules m\u00e9dicamenteuses \u00e9tant diffus\u00e9es de mani\u00e8re constante et continue, ce qui permet une meilleure couverture th\u00e9rapeutique.<\/li>\n<li><strong>Une meilleure s\u00e9curit\u00e9 du patient<\/strong>, avec des risques plus limit\u00e9s de surdosages, d\u2019administrations non ou mal cibl\u00e9es, ou d\u2019oubli de prise du m\u00e9dicament.<\/li>\n<li><strong>Des effets ind\u00e9sirables notablement r\u00e9duits <\/strong>gr\u00e2ce \u00e0 la biocompatibilit\u00e9 et biod\u00e9gradabilit\u00e9 totale de l\u2019implant qui ne lib\u00e9rera aucun d\u00e9riv\u00e9 de d\u00e9gradation toxique dans le corps<\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-4\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-4-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-4-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"5\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p>Ce nouveau \u00ab bioplastique \u00bb 100 % naturel et implantable pourrait remplacer \u00e0 terme les solutions actuelles utilisant des polym\u00e8res de synth\u00e8se et de ce fait moins bien tol\u00e9r\u00e9s par l\u2019organisme. <strong>Les pathologies n\u00e9cessitant des traitements r\u00e9p\u00e9t\u00e9s - cancers, maladies chroniques mais aussi aigu\u00ebs (ex. infections) - figurent au rang des premiers domaines applicatifs<\/strong>.<\/p>\n<p>ALBUPAD repose sur les<strong> travaux de recherche d\u2019Eya ALOUI, Docteure en Pharmacie et Docteure en Chimie des Mat\u00e9riaux, encadr\u00e9e par le Dr. Philippe LAVALLE <\/strong>(laboratoire Biomat\u00e9riaux et Bioing\u00e9nierie, UMR_S 1121 \/ Inserm \u2013 Universit\u00e9 de Strasbourg)<strong> et le Dr. Beno\u00eet FRISCH<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a> <\/strong>(\u00e9quipe 3Bio du laboratoire CAMB, UMR 7199 \/ CNRS \u2013 Universit\u00e9 de Strasbourg).<\/p>\n<p><em><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> Le Dr Beno\u00eet FRISCH a rejoint depuis janvier 2024 le Laboratoire Biomat\u00e9riaux et Bioing\u00e9nierie, UMR_S 1121 \/ Inserm \u2013 Universit\u00e9 de Strasbourg<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div><\/div><\/div><div id=\"pgc-40702-4-1\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-4-1-0\" class=\"so-panel widget widget_media_image panel-first-child panel-last-child\" data-index=\"6\" ><div style=\"width: 310px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"233\" src=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD-300x233.jpg\" class=\"image wp-image-40725  attachment-medium size-medium\" alt=\"\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD-300x233.jpg 300w, https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD-1024x796.jpg 1024w, https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD-150x117.jpg 150w, https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD-768x597.jpg 768w, https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD-1536x1194.jpg 1536w, https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD-2048x1592.jpg 2048w, https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD-500x389.jpg 500w, https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD-600x467.jpg 600w, https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD-129x100.jpg 129w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><p class=\"wp-caption-text\">Eya ALOUI &amp; Jordan BEURTON, CEO et CSO de la nouvelle startup \u00a9ALBUPAD<\/p><\/div><\/div><\/div><\/div><div id=\"pg-40702-5\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-5-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-5-0-0\" class=\"so-panel widget widget_sow-testimonials panel-first-child panel-last-child\" data-index=\"7\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-testimonials so-widget-sow-testimonials-default-c829a459a33f-40702\"\n\t\t\t\n\t\t><div class=\"sow-testimonials\">\n\t\t\t\t\t<div class=\"sow-testimonial-wrapper sow-user-left sow-layout-side\">\n\t\t\t<div class=\"sow-testimonial\">\n\t\t\t\t\n\t\t\t\t<div class=\"sow-testimonial-user\">\n\t\t\t\t\t\t\t\t\t\t<div class=\"sow-image-wrapper sow-image-wrapper-shape-round\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"sow-round-image-frame\" style=\"background-image: url( https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/2_Eya-ALOUI-et-Jordan-BEURTON_\u00a9ALBUPAD.png );\"><\/div>\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"sow-text\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"sow-testimonial-name\"><strong><\/strong><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t<div class=\"sow-testimonial-text\">\n\t\t\t\t\t\t<p><em><strong>Laur\u00e9ate des concours d\u2019innovation Mature your PhD\u00a0en 2020 et\u00a0i-PhD en 2021, Eya ALOUI, CEO et co-fondatrice d\u2019ALBUPAD aux c\u00f4t\u00e9s du Dr. Jordan BEURTON, confirme le potentiel majeur<\/strong> : \u00ab Les mol\u00e9cules antitumorales sont habituellement inject\u00e9es aux patients par voie intraveineuse. Ces th\u00e9rapies g\u00e9n\u00e8rent beaucoup d\u2019effets ind\u00e9sirables pour un r\u00e9sultat limit\u00e9. Gr\u00e2ce \u00e0 la technologie de rupture ALBUPAD qui se base sur une approche verte - le nouveau bioplastique qui permet de fabriquer ces implants est 100% biod\u00e9gradable et biocompatible -, nous sommes par exemple en mesure de charger la mol\u00e9cule antitumorale dans un petit dispositif qu\u2019on implante directement dans la tumeur. Celui-ci va lib\u00e9rer de mani\u00e8re uniforme et continue les m\u00e9dicaments, maximisant ainsi l\u2019exposition de la tumeur \u00e0 l\u2019antitumoral sans lib\u00e9rer des d\u00e9riv\u00e9s de d\u00e9gradation toxiques dans le reste de l\u2019organisme. Nous sommes convaincus que l\u2019albumine, qui constitue ce bioplastique, est le candidat id\u00e9al pour le d\u00e9veloppement de th\u00e9rapies innovantes et de mat\u00e9riaux pour la sant\u00e9. Cette d\u00e9couverte ouvre \u00e9galement la voie pour le d\u00e9veloppement d\u2019un implant \u00ab intelligent \u00bb capable de cibler les tumeurs \u00bb.<\/em><\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-6\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-6-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-6-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"8\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<h2 style=\"text-align: center;\"><strong>Une success story exemplaire<\/strong><\/h2>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-7\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-7-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-7-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"9\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><strong>Le projet ALBUPAD, fruit de\u00a06 ann\u00e9es de recherche et d\u00e9veloppement, a b\u00e9n\u00e9fici\u00e9 de plusieurs soutiens fondateurs\u00a0:<\/strong><\/p>\n<ul>\n<li><strong>La <a href=\"https:\/\/www.conectus.fr\/\">SATT CONECTUS<\/a> (Strasbourg) a investi plus de 600 k\u20ac<\/strong> <strong>pour guider cette technologie innovante du laboratoire vers le march\u00e9<\/strong>. Ce soutien strat\u00e9gique a permis de prot\u00e9ger les d\u00e9couvertes scientifiques (brevet europ\u00e9en d\u00e9pos\u00e9 en\u00a02019), de renforcer et valider scientifiquement cette technologie de rupture naissante, de d\u00e9montrer la validit\u00e9 du projet \u00e0 l\u2019\u00e9chelle pr\u00e9-industrielle, d\u2019identifier les d\u00e9bouch\u00e9s \u00e9conomiques (\u00e9tude de march\u00e9, identification de futurs partenaires industriels), et enfin de structurer le projet de cr\u00e9ation de startup en faisant notamment monter en comp\u00e9tences Eya ALOUI, chercheuse et future CEO, sur tous les aspects March\u00e9.<\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-8\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-8-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-8-0-0\" class=\"so-panel widget widget_sow-testimonials panel-first-child panel-last-child\" data-index=\"10\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-testimonials so-widget-sow-testimonials-default-c829a459a33f-40702\"\n\t\t\t\n\t\t><div class=\"sow-testimonials\">\n\t\t\t\t\t<div class=\"sow-testimonial-wrapper sow-user-left sow-layout-side\">\n\t\t\t<div class=\"sow-testimonial\">\n\t\t\t\t\n\t\t\t\t<div class=\"sow-testimonial-user\">\n\t\t\t\t\t\t\t\t\t\t<div class=\"sow-image-wrapper sow-image-wrapper-shape-round\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"sow-round-image-frame\" style=\"background-image: url( https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/marc_gillmann_president_conectus_cconectus.fr_bd.png );\"><\/div>\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"sow-text\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"sow-testimonial-name\"><strong><\/strong><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t<div class=\"sow-testimonial-text\">\n\t\t\t\t\t\t<p><em><strong>Marc GILLMANN, Pr\u00e9sident de la SATT Conectus\u00a0<\/strong>: \u00ab ALBUPAD, c\u2019est un parcours sans faute, un bel exemple de la synergie multi-partenariale qui existe ici en Alsace et qui facilite la transformation de l\u2019essai : faire qu\u2019une d\u00e9couverte de chercheurs en laboratoire devienne un produit innovant, industrialis\u00e9 \u00e0 grande \u00e9chelle et accessible \u00e0 tous au sein de la soci\u00e9t\u00e9. Notre mission, bien s\u00fbr, c\u2019est de cr\u00e9er une dynamique d\u2019innovation, d\u2019acc\u00e9l\u00e9rer la comp\u00e9titivit\u00e9 de nos entreprises et de cr\u00e9er des startups innovantes \u00e0 fort potentiel. Mais c\u2019est avant tout de donner vie aux belles inventions acad\u00e9miques, pour r\u00e9pondre aux enjeux des transformations soci\u00e9tales et environnementales \u00bb.<\/em><\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-9\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-9-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-9-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"11\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<ul>\n<li>Le <strong><a href=\"https:\/\/www.carnot-mica.fr\/\">Carnot MICA<\/a><\/strong>\u00a0(Mulhouse) s\u2019est quant \u00e0 lui mobilis\u00e9 d\u00e8s le d\u00e9but de l\u2019aventure ALBUPAD,<strong> en investissant 50 k\u20ac sur la premi\u00e8re phase exploratoire de recherche. <\/strong><\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-10\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-10-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-10-0-0\" class=\"so-panel widget widget_sow-testimonials panel-first-child panel-last-child\" data-index=\"12\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-testimonials so-widget-sow-testimonials-default-c829a459a33f-40702\"\n\t\t\t\n\t\t><div class=\"sow-testimonials\">\n\t\t\t\t\t<div class=\"sow-testimonial-wrapper sow-user-left sow-layout-side\">\n\t\t\t<div class=\"sow-testimonial\">\n\t\t\t\t\n\t\t\t\t<div class=\"sow-testimonial-user\">\n\t\t\t\t\t\t\t\t\t\t<div class=\"sow-image-wrapper sow-image-wrapper-shape-round\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"sow-round-image-frame\" style=\"background-image: url( https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/03\/1620746012395.png );\"><\/div>\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"sow-text\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"sow-testimonial-name\"><strong><\/strong><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t<div class=\"sow-testimonial-text\">\n\t\t\t\t\t\t<p><strong>Lionel LIMOUSY, son Directeur, t\u00e9moigne\u00a0: <\/strong><em>\u00ab\u00a0Le financement du Carnot MICA a permis de d\u00e9velopper de nouveaux biomat\u00e9riaux \u00e0 base d\u2019albumine et de d\u00e9risquer un projet innovant, permettant de lancer les phases de d\u00e9veloppement. Nous sommes tr\u00e8s fiers d\u2019avoir accompagn\u00e9 ALBUPAD \u00e0 ses tout d\u00e9buts et de voir le fruit d\u2019un travail de plus 6 ans se concr\u00e9tiser par la cr\u00e9ation d\u2019une nouvelle startup biotech en Alsace\u00a0\u00bb.<\/em><\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-11\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-11-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-11-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"13\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p>Le projet ALBUPAD a \u00e9galement b\u00e9n\u00e9fici\u00e9 du <strong>soutien financier de la <a href=\"https:\/\/www.ligue-cancer.net\/\"><em>Ligue contre le cancer <\/em><\/a>(53 k\u20ac) et d\u2019<a href=\"https:\/\/alsacecontrecancer.com\/\"><em>Alsace contre le Cancer<\/em><\/a> (15 k\u20ac). <\/strong><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-12\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-12-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-12-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"14\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<h2 style=\"text-align: center;\"><strong>Servir la canc\u00e9rologie, et bien plus\u2026<\/strong><\/h2>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-13\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-13-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-13-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"15\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p>La startup ALBUPAD est <strong>actuellement incub\u00e9e chez SEMIA \/ QUEST FOR HEALTH \u00e0 Strasbourg<\/strong>. Elle est <strong>soutenue par Bpifrance \u00e0 travers la bourse FrenchTech Personne Physique (30 k\u20ac) et par la R\u00e9gion Grand Est \u00e0 travers la bourse au porteur de projet (30 k\u20ac).<\/strong> Des lev\u00e9es de fonds d\u2019amor\u00e7ages sont envisag\u00e9es pour couvrir les besoins g\u00e9n\u00e9r\u00e9s par les prochaines phases de R&amp;D (caract\u00e9risation produit et industrialisation).<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-40702-14\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-14-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-14-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"16\" ><div class=\"panel-widget-style panel-widget-style-for-40702-14-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p>Forte de ses\u00a05 membres co-fondateurs, les prochaines \u00e9tapes cl\u00e9s de d\u00e9veloppement d\u2019ALBUPAD consisteront \u00e0 <strong>valider l\u2019industrialisation du proc\u00e9d\u00e9 de fabrication<\/strong> et \u00e0 <strong>finaliser des \u00e9tudes in vivo de d\u00e9livrance et d\u2019efficacit\u00e9<\/strong> de nouvelles mol\u00e9cules avec le mat\u00e9riau ALBUPAD. Pr\u00e9vues en 2024, ces \u00e9tapes-cl\u00e9s permettront de s\u00e9duire de futurs investisseurs industriels. <strong>Des essais cliniques seront \u00e9galement envisag\u00e9s \u00e0 horizon\u00a02030 en co-d\u00e9veloppement avec un partenaire industriel pharmaceutique.<\/strong><\/p>\n<p><strong>L\u2019enjeu est de taille<\/strong>. Estim\u00e9 \u00e0 15 milliards en 2022, le march\u00e9 des formulations de d\u00e9livrance prolong\u00e9e de m\u00e9dicaments concerne les syst\u00e8mes administr\u00e9s localement et permettant d\u2019obtenir une lib\u00e9ration locale et syst\u00e9mique. Parmi les acteurs cl\u00e9s au sein de ces march\u00e9s se dressent plusieurs industriels pharmaceutiques tels que Takeda, Novartis, Merck, Pfizer, Teva, GSK et AstraZeneca. Par ailleurs, les mat\u00e9riaux biosourc\u00e9s \u00e0 base de prot\u00e9ines peuvent concerner de nombreux autres march\u00e9s, tels que <strong>les produits v\u00e9t\u00e9rinaires, cosm\u00e9tiques, nutraceutiques, ou encore la substitution de plastiques de synth\u00e8ses pour des usages au quotidien<\/strong>.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><div id=\"pg-40702-15\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-40702-15-0\"  class=\"panel-grid-cell\" ><div id=\"panel-40702-15-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"17\" ><div class=\"panel-widget-style panel-widget-style-for-40702-15-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p style=\"text-align: center;\"><a href=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/02\/CP_ALBUPAD_def.pdf_0.pdf\"><strong><span style=\"color: #ffffff; font-size: 16pt;\"><span style=\"font-size: 16pt;\">Le communiqu\u00e9 de presse<\/span><\/span><\/strong><\/a><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>#Un mat\u00e9riau innovant pour r\u00e9volutionner la d\u00e9livrance de m\u00e9dicaments ! La nouvelle startup ALBUPAD vient de voir le jour \u00e0 Strasbourg, propuls\u00e9e par la SATT Conectus avec le soutien d\u00e9terminant du Carnot MICA. Spin-off de deux laboratoires de recherche publique strasbourgeois et incub\u00e9e chez SEMIA, ALBUPAD propose un nouveau mat\u00e9riau innovant \u00e0 base d\u2019albumine, 100% [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":40674,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[568,604],"tags":[],"class_list":["post-40702","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-successstories-en","category-startup-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La Success Story du mois : ALBUPAD - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/albupad\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/albupad\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/albupad\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"headline\":\"La Success Story du mois : ALBUPAD\",\"datePublished\":\"2024-03-27T09:00:13+00:00\",\"dateModified\":\"2024-03-27T09:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/albupad\/\"},\"wordCount\":1006,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/albupad\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/Albupad.jpg\",\"articleSection\":[\"Success Stories\",\"Start-up\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/albupad\/\",\"url\":\"https:\/\/www.satt.fr\/en\/albupad\/\",\"name\":\"La Success Story du mois : ALBUPAD - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/albupad\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/albupad\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/Albupad.jpg\",\"datePublished\":\"2024-03-27T09:00:13+00:00\",\"dateModified\":\"2024-03-27T09:03:28+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/albupad\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/albupad\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/albupad\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/Albupad.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/Albupad.jpg\",\"width\":1614,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/albupad\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La Success Story du mois : ALBUPAD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\",\"name\":\"admin\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La Success Story du mois : ALBUPAD - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/albupad\/","twitter_misc":{"Written by":"admin","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/albupad\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/albupad\/"},"author":{"name":"admin","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"headline":"La Success Story du mois : ALBUPAD","datePublished":"2024-03-27T09:00:13+00:00","dateModified":"2024-03-27T09:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/albupad\/"},"wordCount":1006,"image":{"@id":"https:\/\/www.satt.fr\/en\/albupad\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/Albupad.jpg","articleSection":["Success Stories","Start-up"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/albupad\/","url":"https:\/\/www.satt.fr\/en\/albupad\/","name":"La Success Story du mois : ALBUPAD - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/albupad\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/albupad\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/Albupad.jpg","datePublished":"2024-03-27T09:00:13+00:00","dateModified":"2024-03-27T09:03:28+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/albupad\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/albupad\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/albupad\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/Albupad.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/03\/Albupad.jpg","width":1614,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/albupad\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"La Success Story du mois : ALBUPAD"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec","name":"admin","url":"https:\/\/www.satt.fr\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/40702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=40702"}],"version-history":[{"count":5,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/40702\/revisions"}],"predecessor-version":[{"id":40839,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/40702\/revisions\/40839"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/40674"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=40702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=40702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=40702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}